Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Cost of Revenue (2023 - 2025)

Mirum Pharmaceuticals (MIRM) has 3 years of Cost of Revenue data on record, last reported at $28.3 million in Q4 2025.

  • For Q4 2025, Cost of Revenue changed N/A year-over-year to $28.3 million; the TTM value through Dec 2025 reached $71.9 million, changed N/A, while the annual FY2025 figure was $100.2 million, 22.78% up from the prior year.
  • Cost of Revenue reached $28.3 million in Q4 2025 per MIRM's latest filing, up from $20.8 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $28.3 million in Q4 2025 and bottomed at $5.0 million in Q1 2023.
  • Average Cost of Revenue over 3 years is $18.0 million, with a median of $19.3 million recorded in 2024.
  • The widest YoY moves for Cost of Revenue: up 258.1% in 2024, down 258.1% in 2024.
  • A 3-year view of Cost of Revenue shows it stood at $5.0 million in 2023, then surged by 317.88% to $20.8 million in 2024, then surged by 35.85% to $28.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $28.3 million in Q4 2025, $20.8 million in Q3 2024, and $17.8 million in Q1 2024.